Cosmos Holdings Inc. Common Stock
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It also provides ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Open COSM dashboard ↗Cardiff Oncology, Inc. Common Stock
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Open CRDF dashboard ↗